Arginine enzymatic deprivation and diet restriction for cancer treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/140174 |
Resumo: | Recent findings in amino acid metabolism and the differences between normal, healthy cells and neoplastic cells have revealed that targeting single amino acid metabolic enzymes in cancer therapy is a promising strategy for the development of novel therapeutic agents. Arginine is derived from dietary protein intake, body protein breakdown, or endogenous de novo arginine production and several studies have revealed disturbances in its synthesis and metabolism which could enhance or inhibit tumor cell growth. Consequently, there has been an increased interest in the arginine-depleting enzymes and dietary deprivation of arginine and its precursors as a potential antineoplastic therapy. This review outlines the most recent advances in targeting arginine metabolic pathways in cancer therapy and the different chemo- and radio-therapeutic approaches to be co-applied. |
id |
USP-31_2e842a8f5d81992fd3f994e3652d19e4 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/140174 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Arginine enzymatic deprivation and diet restriction for cancer treatmentArginine-depleting enzyme/antineoplastic therapyDietary deprivationRecent findings in amino acid metabolism and the differences between normal, healthy cells and neoplastic cells have revealed that targeting single amino acid metabolic enzymes in cancer therapy is a promising strategy for the development of novel therapeutic agents. Arginine is derived from dietary protein intake, body protein breakdown, or endogenous de novo arginine production and several studies have revealed disturbances in its synthesis and metabolism which could enhance or inhibit tumor cell growth. Consequently, there has been an increased interest in the arginine-depleting enzymes and dietary deprivation of arginine and its precursors as a potential antineoplastic therapy. This review outlines the most recent advances in targeting arginine metabolic pathways in cancer therapy and the different chemo- and radio-therapeutic approaches to be co-applied.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/14017410.1590/s2175-97902017000300200Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 3 (2017); e00200-Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 3 (2017); e00200-Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 3 (2017); e00200-2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/140174/135320Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessZam, Wissam2017-10-27T12:48:20Zoai:revistas.usp.br:article/140174Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2017-10-27T12:48:20Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
title |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
spellingShingle |
Arginine enzymatic deprivation and diet restriction for cancer treatment Zam, Wissam Arginine-depleting enzyme/antineoplastic therapy Dietary deprivation |
title_short |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
title_full |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
title_fullStr |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
title_full_unstemmed |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
title_sort |
Arginine enzymatic deprivation and diet restriction for cancer treatment |
author |
Zam, Wissam |
author_facet |
Zam, Wissam |
author_role |
author |
dc.contributor.author.fl_str_mv |
Zam, Wissam |
dc.subject.por.fl_str_mv |
Arginine-depleting enzyme/antineoplastic therapy Dietary deprivation |
topic |
Arginine-depleting enzyme/antineoplastic therapy Dietary deprivation |
description |
Recent findings in amino acid metabolism and the differences between normal, healthy cells and neoplastic cells have revealed that targeting single amino acid metabolic enzymes in cancer therapy is a promising strategy for the development of novel therapeutic agents. Arginine is derived from dietary protein intake, body protein breakdown, or endogenous de novo arginine production and several studies have revealed disturbances in its synthesis and metabolism which could enhance or inhibit tumor cell growth. Consequently, there has been an increased interest in the arginine-depleting enzymes and dietary deprivation of arginine and its precursors as a potential antineoplastic therapy. This review outlines the most recent advances in targeting arginine metabolic pathways in cancer therapy and the different chemo- and radio-therapeutic approaches to be co-applied. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/140174 10.1590/s2175-97902017000300200 |
url |
https://www.revistas.usp.br/bjps/article/view/140174 |
identifier_str_mv |
10.1590/s2175-97902017000300200 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/140174/135320 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 53 Núm. 3 (2017); e00200- Brazilian Journal of Pharmaceutical Sciences; v. 53 n. 3 (2017); e00200- Brazilian Journal of Pharmaceutical Sciences; Vol. 53 No. 3 (2017); e00200- 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222913282965504 |